Heparin as a therapy for COVID-19: current evidence and future possibilities

JA Hippensteel, WB LaRiviere… - … of Physiology-Lung …, 2020 - journals.physiology.org
Coronavirus disease 2019 (COVID-19), the clinical syndrome associated with infection by
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has impacted nearly every …

Comprehensive landscape of heparin therapy for COVID-19

C Shi, W Tingting, JP Li, MA Sullivan, C Wang… - Carbohydrate …, 2021 - Elsevier
The pandemic coronavirus disease 2019 (COVID-19), caused by the infection of severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is rapidly spreading globally …

[HTML][HTML] The potential role of heparin in patients with COVID-19: beyond the anticoagulant effect. A review

L Gozzo, P Viale, L Longo, DC Vitale… - Frontiers in …, 2020 - frontiersin.org
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is responsible of
variable clinical manifestations, ranging from no symptoms to severe pneumonia with acute …

[HTML][HTML] Inhaled and systemic heparin as a repurposed direct antiviral drug for prevention and treatment of COVID-19

C Conzelmann, JA Müller, L Perkhofer, KMJ Sparrer… - Clinical Medicine, 2020 - Elsevier
Here, we advocate a highly favourable opportunity for the treatment of COVID-19 disease by
repurposing a long-serving medical agent with an excellent history of clinical use, namely …

Using heparin molecules to manage COVID‐2019

J Liu, J Li, K Arnold, R Pawlinski… - Research and practice …, 2020 - Wiley Online Library
Abstract The coronavirus disease 2019 (COVID‐19) pandemic is becoming one of the
largest global public health crises in modern history. The race for an effective drug to prevent …

[HTML][HTML] Heparin–an old drug with multiple potential targets in Covid‐19 therapy

U Lindahl, JP Li - Journal of Thrombosis and Haemostasis, 2020 - jthjournal.org
2. Dianne K, Jennings I, Kitchen S, Walker I. Letter in response to article “Systematic review
of viscoelastic testing (TEG/Rotem) in obstetrics and recommendations from the women's …

Heparin: An old drug for new clinical applications

P Wang, L Chi, Z Zhang, H Zhao, F Zhang… - Carbohydrate …, 2022 - Elsevier
Heparin, an old but first-line anticoagulant, has been used over a century. It is a
heterogeneous, linear, highly sulfated, anionic glycosaminoglycan with a broad distribution …

Randomized trials of therapeutic heparin for COVID‐19: a meta‐analysis

M Sholzberg, BR da Costa, GH Tang… - … and practice in …, 2021 - Wiley Online Library
Background Pulmonary endothelial injury and microcirculatory thromboses likely contribute
to hypoxemic respiratory failure, the most common cause of death, in patients with COVID …

[HTML][HTML] The versatile heparin in COVID‐19

J Thachil - Journal of Thrombosis and Haemostasis, 2020 - jthjournal.org
Coagulopathy in coronavirus infection has been shown to be associated with high mortality
with high D-dimers being a particularly important marker for the coagulopathy. 1 In the latest …

[HTML][HTML] Beneficial non-anticoagulant mechanisms underlying heparin treatment of COVID-19 patients

B Buijsers, C Yanginlar, ML Maciej-Hulme… - …, 2020 - thelancet.com
Abstract Coronavirus disease-2019 (COVID-19) is associated with severe inflammation in
mainly the lung, and kidney. Reports suggest a beneficial effect of the use of heparin/low …